RX108

RX108 is a novel, potent small-molecule inhibitor of sodium-potassium adenosine triphosphatase (Na+/K+-ATPase), developed primarily for the treatment of various solid tumors, including hepatocellular carcinoma and other advanced malignancies. Mechanistically, RX108 inhibits Na+/K+-ATPase activity in cancer cells, which disrupts ion transport and triggers downstream signaling events leading to cell-cycle arrest, apoptosis, and autophagic cell death. Preclinical studies have shown that RX108 also downregulates alanine serine cysteine transporter 2 (ASCT2), reducing glutamine uptake and metabolism—an effect particularly relevant in glutamine-addicted cancers such as hepatocellular carcinoma. The drug is currently under clinical development with ongoing Phase 1 and Phase 2 trials for multiple solid tumor indications[1][2][3][4][5].

Other names

sodium-potassium adenosine triphosphatase inhibitor rx108Na/K-ATPase inhibitor RX108